Cargando…

Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy

Objective: We examined whether epidermal growth factor receptor (EGFR) expression in circulating tumor cells (CTCs) can be used to predict survival in a population of bone-metastatic castration-resistant prostate cancer (mCRPC) patients treated with docetaxel chemotherapy. Methods: All patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okegawa, Takatsugu, Itaya, Naoshi, Hara, Hidehiko, Tambo, Mitsuhiro, Nutahara, Kikuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187808/ https://www.ncbi.nlm.nih.gov/pubmed/27916908 http://dx.doi.org/10.3390/ijms17122008

Ejemplares similares

Predictors of septic shock in obstructive acute pyelonephritis
por: Tambo, Mitsuhiro, et al.
Publicado: (2013)

Distinguishing testicular torsion from torsion of the appendix testis by clinical features and signs in patients with acute scrotum
por: Fujita, Naoyuki, et al.
Publicado: (2017)

Serum level and immunohistochemical expression of vascular endothelial growth factor for the prediction of postoperative recurrence in renal cell carcinoma
por: Fujita, Naoyuki, et al.
Publicado: (2014)

Vesicoenteric Fistula Arising from an Adenocarcinoma of Ectopic Pancreatic Tissue in a Meckel Diverticulum
por: Fujita, Naoyuki, et al.
Publicado: (2018)

Kidney volume and function in autosomal dominant polycystic kidney disease
por: Higashihara, Eiji, et al.
Publicado: (2013)

A potentially crucial role of the PKD1 C-terminal tail in renal prognosis
por: Higashihara, Eiji, et al.
Publicado: (2017)

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer
por: Lin, H-M, et al.
Publicado: (2014)

Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases
por: Higashihara, Eiji, et al.
Publicado: (2018)

Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD
por: Higashihara, Eiji, et al.
Publicado: (2021)

Presepsin and procalcitonin as predictors of sepsis based on the new Sepsis-3 definitions in obstructive acute pyelonephritis
por: Tambo, Mitsuhiro, et al.
Publicado: (2020)

Intratumor Heterogeneity in Primary Kidney Cancer Revealed by Metabolic Profiling of Multiple Spatially Separated Samples within Tumors
por: Okegawa, Takatsugu, et al.
Publicado: (2017)

Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease?
por: Higashihara, Eiji, et al.
Publicado: (2014)

Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy
por: Yamashita, Shimpei, et al.
Publicado: (2016)

Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
por: Isaksson, Jenny, et al.
Publicado: (2021)

Effects on Depression and Anxiety After Mid-Urethral Sling Surgery for Female Stress Urinary Incontinence
por: Kinjo, Manami, et al.
Publicado: (2020)

Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report
por: Kitamura, Junji, et al.
Publicado: (2021)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
por: Vermunt, Marit A. C., et al.
Publicado: (2022)

Predictive Factors for Premature Discontinuation of Docetaxel-Based Systemic Chemotherapy in Men With Castration-Resistant Prostate Cancer
por: Park, Seung Chol, et al.
Publicado: (2013)

KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients
por: Schäfer, Georg, et al.
Publicado: (2021)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Laparoscopic retroperitoneal lymph node dissection versus open retroperitoneal lymph node dissection for testicular cancer: A comparison of clinical and perioperative outcomes
por: Shishido, Toshihide, et al.
Publicado: (2022)

A case of castration-resistant prostate cancer with liver metastases achieved a complete response by docetaxel chemotherapy
por: Shirotake, Suguru, et al.
Publicado: (2020)

Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy
por: Min, Kyungchan, et al.
Publicado: (2020)

Relationships of body composition and adipocytokines with outcomes in metastatic castration-resistant prostate cancer patients receiving docetaxel chemotherapy
por: Li, Jun-Hong, et al.
Publicado: (2023)

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
por: Wilson, C, et al.
Publicado: (2008)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
por: Wong, Hui-Li, et al.
Publicado: (2015)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

γ-Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer
por: Onishi, Kenta, et al.
Publicado: (2020)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Laparoscopic radical prostatectomy versus robot-assisted radical prostatectomy: comparison of oncological outcomes at a single center
por: Okegawa, Takatsugu, et al.
Publicado: (2020)

Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel‐sensitive and docetaxel‐resistant castration‐resistant prostate cancer cells
por: Li, Senmao, et al.
Publicado: (2021)

Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report
por: Daverede, Luis, et al.
Publicado: (2014)

Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed
por: Lee, J-L, et al.
Publicado: (2014)

Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
por: Ku, ShengYu, et al.
Publicado: (2014)

The Influence of Prednisone on the Efficacy of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Teply, Benjamin A., et al.
Publicado: (2015)

Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells
por: Wang, Quan, et al.
Publicado: (2018)

Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells
por: Tanaudommongkon, Irin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7723e8gnnr1bgv6ijsa07us7ob